State of The Art Treatment for Hepatitis C

Media Formats

ReachMD Healthcare Image

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Details

Presenters

Comments

Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.

Jorge Herrera, MD

Jorge Herrera, MD

Leslie P. Lundt, MD

Leslie P. Lundt, MD

Recommended

Details

Presenters

Comments

Overview
Since 2001, combination therapy with pegylated interferon with ribavirin is considered the standard of care in hepatitis C treatment. In clinical trials, 50 to 60 percent of patients treated with combination therapy achieved a sustained virologic response, or SVR, meaning the virus is undetectable in their blood. Dr. Jorge Herrera joins host Dr. Leslie Lundt to discuss the state of the art for treatment of Hepatitis C.

Jorge Herrera, MD

Jorge Herrera, MD

Leslie P. Lundt, MD

Leslie P. Lundt, MD

Program Chapters

Segment Chapters

Playlist:

Recommended